Treatment Options, Clinical Pathways, and Collaborative Care: A Multiple Myeloma Update for Managed Care and Specialty Pharmacy Web Activity

Yelak Biru
Patient Advocate
North Texas Myeloma Support Group
IMF Global Myeloma Action Network

Click here for biography
Jeffrey Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
MagellanRx Management

Click here for biography
Carol Ann Huff, MD
Associate Professor of Oncology and Medicine
Director, Multiple Myeloma Program
Medical Director, Department of Oncology Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Click here for biography
Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC

Click here for biography



The management of multiple myeloma (MM) is a priority area for MCOs in order to optimize clinically- and economically-appropriate care for their members. As novel agents become available, treatment decision making is becoming more complex and MCOs and other payer organizations need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes. Guidance is needed for the target audience to implement current guidelines, utilize clinical pathways, design appropriate medical and pharmacy benefits, and implement effective specialty pharmacy management services.

This interactive program is designed to engage the faculty and audience to develop solutions for managed care professionals to implement within their own setting to improve outcomes for patients with MM. Multidisciplinary faculty will be utilized featuring a managed care medical director, a pharmacy director, and a hematology/oncology expert.

An innovative approach to the activity's curriculum will feature a multiple myeloma patient testimonial and three faculty demonstrating the unique value each brings to the overall care of patients with MM through real world examples and case studies. By working together via data sharing and collaboration between payers, hematologists/oncologists, specialty pharmacy, and patients, on a more integrated approach, current barriers will be overcome, demonstrating value to all parties and motivating them to become further engaged.

After completing this activity, the participant should be better able to:


Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-18-146-H04-P

Type of Activity: Knowledge

Continuing Nursing Education
The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.1 contact hours is provided by the Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter Reported Financial Relationship
Yelak Biru Consulting Fees (eg, advisory boards): Takeda Oncology
Jeffrey Dunn, PharmD, MBA No financial interest/relationships relating to the topic of this activity
Carol Ann Huff, MD Consulting Fees (eg, advisory boards): Glenmark, Karyopharm
Contracted Research: Karyopharm, Prothena
Edmund Pezalla, MD, MPH No financial interest/relationships relating to the topic of this activity

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating and receiving CME/CE credit for this activity. During the period October 1, 2017 through April 30, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.


There is no fee for this educational activity.